Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry
Background: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU’s usefulness in everyday clinical practice. Objectives: To assess the effectiveness of S...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X251315138 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|